Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.


TSXV:CZO - Post by User

Post by prophetoffactzon May 23, 2024 9:20am
106 Views
Post# 36053684

Q3 is a defining moment

Q3 is a defining momentCZO's merger with AEZS is expected to close in Q3(June 3).

Top line results from AEZS's pediatric clinical trial are expected in Q3.

100L PGX scale-up commissioning, the decision point for mass industrialization, is expected in Q3.

50L PGX scale-up was said "almost complete" last news release and previously was said to provide materials for potential partners to evaluate. A filing with Health Canada could be made for potential approval of the first PGX product.

In Q3 the company should complete the single escalating dose portion of its avenanthramide clinical study. PGX-fibrosis was said to require a short study previously and a comprehensive package has been sent for publication to the journal Biomaterials.    
<< Previous
Bullboard Posts
Next >>